Pfizer Inc. (PFE)
|Net Income (ttm)||9.62B|
|Trading Day||May 10|
|Day's Range||39.78 - 40.28|
|52-Week Range||30.35 - 42.20|
Pfizer begins process of seeking full U.S. vaccine approval: RPT
Yahoo Finance's Anjalee Khemlani reports on Pfizer pharmaceutical company seeking full approval in the United States. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://yo...
Moderna and Pfizer vaccines show defense against variants
Associate Faculty Director at the Harvard Global Health Institute Dr. Ingrid Katz joined Yahoo Finance Live to break down the latest news on vaccines as Pfizer and Biontech seek full FDA approval Watch ...
Strong growth in revenue and earnings wasn't the only story in the company's latest quarterly update.
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Moderna and Pfizer vaccines show defense against variants
Associate Faculty Director at the Harvard Global Health Institute Dr. Ingrid Katz joined Yahoo Finance Live to break down the latest news on vaccines as Pfizer and Biontech seek full FDA approval. Watch...
EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots
European Medical Agency (EMA) is reviewing reports of a rare nerve-degenerating disorder in people who received AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, raising new questions about potential si...
Pfizer's CEO said the waiver proposal "will unleash a scramble for the critical inputs we require in order to make a safe and effective vaccine.'
Pfizer and BioNTech have submitted an application for full FDA approval of their COVID-19 vaccine.
PFE vs. NVO: Which Stock Is the Better Value Option?
Pfizer began applying for full approval on Friday, a process that could take months.
Pfizer and BioNTech asked for full Food and Drug Administration approval of their Covid vaccine on Friday, leading BioNTech stock to pop. That followed patent questions that hurt shares.
Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) have started the process to seek full approval from the U.S. Food and Drug Administration (FDA) for a COVID-19 vaccine. What Happened: The co...
It's currently being administered in the US under an emergency use authorization.
The companies are the first COVID vaccine makers in the nation to apply for full approval, which would allow Pfizer to market the vaccine directly to consumers.
The Pfizer shot was the first Covid-19 vaccine to be approved under an emergency use authorization in December.
This strong performance can be attributed to a very high demand for Pfizer's Covid-19 vaccine, which garnered $3.5 billion in Q1 sales. While the company also revised its full-year 2021 EPS guidance upw...
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S. Food and Drug Adm...
It could determine the future success of the company's COVID-19 vaccine.
Oppenheimer health care analyst on whether vaccine makers should lose sleep over patent waivers
Hartaj Singh, Oppenheimer & Co, on Covid vaccine makers under pressure as the patent waiver conversation continues. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Pete Najarian, Jeff Mil...
Mizuho Securities' Vamil Divan expresses concern about the company's post-coronavirus future.
Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.
12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.
U.S. backs COVID-19 vaccine patent waiver
Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are donating doses of their COVID-19 vaccine to athletes participating in this summer's Olympic and Paralympic Games in Tokyo. What Happened: The p...
Moderna, Pfizer drop after US backs proposal to lift patent protection for COVID-19 vaccines to boost supply
The US has backed a proposal first put forward by India and South Africa for a temporary waiver on COVID-19 vaccine patents. “The administration believes strongly in intellectual property protections, b...
Coronavirus: Moderna says tweaked vaccine works against variants, two BioNTech/Pfizer doses give 95% protection
Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African ...
Pfizer, Moderna Shares Plummet As Key Vaccine-Making Countries Line Up Behind Biden's Covid Patent Waiver Plans
The Biden administration is backing international plans to suspend intellectual property protections.
If enacted, such a move would hit the smaller vaccine makers particularly hard.
Vaccine makers sink as Biden considers waving patents
Brent Saunders, former Allergan CEO, on who will make the vaccine next time. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Nadine Terman.
Single Shot Of AstraZeneca, Pfizer COVID-19 Vaccines Provide 87% Protection, South Korea Study Shows: Reuters
According to real-world data released by South Korea, one dose of COVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) was 86.6% effective in prev...
Pfizer's Inc (NYSE: PFE) Hospira will recall one lot of each of the injectable hospital anesthetics bupivacaine hydrochloride (HCL) and lidocaine HCL following an investigation revealing that a portion ...
Final Trades: Marathon Petroleum, Corteva, Pfizer & more
The "Halftime Report" traders give their top picks to watch for the second half.
Is (PFE) Outperforming Other Medical Stocks This Year?
The country's health agency credited the change to Pfizer's March trial data in adolescents.
Probably not, but the study could benefit another vaccine maker.
Ocugen may be able to handle one of the biggest challenges facing vaccine makers.
AstraZeneca And Pfizer Covid-19 Vaccines More Than 86% Effective After First Dose, South Korean Authorities Say
The Pfizer shot was 89.7% effective, and AstraZeneca was 86% effective in preventing infections among people over-60 after a single dose, according to South Korean officials.
FDA to authorize Pfizer Covid vaccine for 12-15 year olds by next week
Meg Tirrell joins 'The News with Shepard Smith' to report what health experts say about vaccinating kids to help prevent Covid-19 transmission.
Pfizer (PFE) closed at $39.95 in the latest trading session, marking a +0.3% move from the prior day.
Before the market opened on May 4, Pfizer Inc. ( PFE , Financial) released its earnings results for the first quarter of 2021.
FDA set to approve Pfizer vaccine for 12-15 year olds: RPT
Yahoo Finance's Adam Shapiro and Anjalee Khemlani discuss coronavirus vaccinations for 12-15 year olds. Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwH...
Pfizer CEO: No variant identified so far that escapes our vaccine protection
CNBC's Kelly Evans and Meg Tirrell talk about what's next for the Pfizer and BioNTech Covid vaccine with Pfizer CEO Albert Bourla.
Pfizer Inc.'s ( PFE , Financial) Covid-19 vaccine is poised to knock AbbVie Inc.'s ( ABBV , Financial) Humira off the top perch and become the best-selling medication in pharmaceutical industry history.
Pfizer Inc (NYSE: PFE) has paused enrollment in a pivotal trial of its anti-BCMA bispecific antibody after seeing three cases of peripheral neuropathy in an earlier-stage study. In February, Pfizer took...
Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021.
Pfizer scientist expects elderly, people with underlying conditions to be first to get Covid booster shots
Mikael Dolsten, Pfizer's chief scientific officer, said it makes sense to start with those most susceptible to Covid.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brand... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Pfizer's revenue was $41.91 billion, an increase of 1.79% compared to the previous year's $41.17 billion. Earnings were $9.62 billion, a decrease of -40.91%.
According to 21 analysts, the average rating for Pfizer stock is "Buy." The 12-month stock price forecast is 41.99, which is an increase of 4.70% from the latest price.